Search
Pixantrone
go.drugbank.com/drugs/DB06193ApprovedWithdrawnIt is similar in structure to anthracyclines such as mitoxantrone, but exerts fewer toxic effects on cardiac tissue. [2] The lower cardio-toxic effects of pixantrone may be explained, in part, by its redox … It is currently being tested in Phase III trials. [2] Although pixantrone has not yet received FDA approval in the United States, it has been granted conditional marketing approval by the European Union
Secukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigational[A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … [L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders.
Potassium
go.drugbank.com/drugs/DB14500ApprovedInvestigationalIt was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for Americans. … [A32222,A38081,L2652] Various pharmacological preparations have been formulated to replenish potassium.
Synonyms: KMixtures: New Chapter's D'adamo 4 Your Type Multiple for Type O, PERIOLIMEL N4-600E İNFÜZYONLUK ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ VE LİPİD EMÜLSİYONU, 1000 MLTocofersolan
go.drugbank.com/drugs/DB11635ApprovedCholestasis is the reduction or stoppage of bile flow, either to impaired secretion by _hepatocytes_ (liver cells) or obstruction [L2374], [L2375]. … It was approved by the European Medicines Agency (EMA) in June 2009 under the market name Vedrop.
Depemokimab
go.drugbank.com/drugs/DB18846ApprovedInvestigational[A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients … [A275338, L54758] Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence.
Larotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigationalIt was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805] … [L49821] Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors.
Iopodic acid
go.drugbank.com/drugs/DB09333ApprovedWithdrawnOn September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status.[L1082] … This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.
Papain
go.drugbank.com/drugs/DB11193ApprovedWithdrawnWhile it has been used for the treatment of inflammation and pain via topical administration, papain has also shown to have anthelmintic and tooth-whitening properties. … The enzyme is found to be localized in the skin of papaya, and is collected from slashed unripe papayas as a crude latex. Papain is used in food, pharmaceutical, textile, and cosmetic industries.
Mixtures: Herbalax Forte No 70 Tab, Neo Life Enzyme TabAvibactam
go.drugbank.com/drugs/DB09060ApprovedInvestigationalThis combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract … infections, including pyelonephritis caused by antibiotic resistant-pathogens, including those caused by multi-drug resistant gram-negative bacterial pathogens.
Chymotrypsin
go.drugbank.com/drugs/DB09375ApprovedInvestigationalVet approvedWithdrawnChymotrypsin is the most abundant pancreatic proteases that represent up to 10-20% of the total protein synthesized by the exocrine pancreas [A32637]. … Chymotrypsin contains both the catalytic triad and oxyanion hole, and the tertiary structure of chymotrypsin is similar to [DB11237] [A32642].